Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

被引：233

作者：

Holst, JJ ^{[1
]}

Deacon, CF ^{[1
]}

机构：

[1] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark

来源：

DIABETOLOGIA | 2005年 / 48卷 / 04期

关键词：

dipeptidyl peptidase-IV; gastric inhibitory polypeptide; gastroenteropancreatic peptide hormones; glucagon-like peptide-1; incretin; incretin effect; oral hypoglycaemic agents; pharmacokinetics; proteolytic processing;

D O I：

10.1007/s00125-005-1705-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：612 / 615

页数：4

共 34 条

[1] Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
Ahrén, B
Landin-Olsson, M
Jansson, PA
Svensson, M
Holmes, D
Schweizer, A
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) : 2078 - 2084
[2] Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
Ahrén, B
Simonsson, E
Larsson, H
Landin-Olsson, M
Torgeirsson, H
Jansson, PA
Sandqvist, M
Båvenholm, P
Efendic, S
Eriksson, JW
Dickinson, S
Holmes, D
[J]. DIABETES CARE, 2002, 25 (05) : 869 - 875
[3] AHREN B, 2004, DIABETES, V53
[4] Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
Balkan, B
Li, X
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (04) : R1449 - R1454
[5] Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor
Burcelin, R
Da Costa, A
Drucker, D
Thorens, B
[J]. DIABETES, 2001, 50 (08) : 1720 - 1728
[6] Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients
Creutzfeldt, WOC
Orskov, C
Kleine, N
Holst, JJ
Willms, B
Nauck, MA
[J]. DIABETES CARE, 1996, 19 (06) : 580 - 586
[7] Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region
Dardevet, D
Moore, MC
Neal, D
DiCostanzo, CA
Snead, W
Cherrington, AD
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 287 (01): : E75 - E81
[8] Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
Deacon, CF
Wamberg, S
Bie, P
Hughes, TE
Holst, JJ
[J]. JOURNAL OF ENDOCRINOLOGY, 2002, 172 (02) : 355 - 362
[9] BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS
DEACON, CF
NAUCK, MA
TOFTNIELSEN, M
PRIDAL, L
WILLMS, B
HOLST, JJ
[J]. DIABETES, 1995, 44 (09) : 1126 - 1131
[10] DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO
DEACON, CF
JOHNSEN, AH
HOLST, JJ
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) : 952 - 957

← 1 2 3 4 →